
TRVI Stock Forecast & Price Target
TRVI Analyst Ratings
Bulls say
Trevi Therapeutics is poised for success with a unique opportunity in the chronic cough market, supported by its strong IP and differentiated mechanism of action. With the recent discontinuation of GSK's rival therapy, Haduvio now has the potential for broader use beyond later-line treatment and could become a blockbuster drug with a peak sales potential of over $6 billion. Additionally, the company has a focused and efficient strategy with a manageable salesforce, and the upcoming catalysts for the IPF pivotal studies could provide further momentum for the stock. Investors should not overlook the potential for Haduvio in the broader market for RCC, as successful lower-dose data from the ongoing LAKE study could expand its use and significantly increase its addressable market.
Bears say
Trevi Therapeutics is facing M&A speculation due to the highly desirable nature of their asset, Haduvio, and its strong potential for addressing unmet needs in the market, with multiple Phase 2 studies and strong IP. This has led to strong projected financials, with expected revenue and EBITDA growth and increasing margins due to the adoption of Yellow Account and processing margins. These factors warrant a Buy rating with a $85 price target based on a 5.5x 2027E EV/sales multiple and 28x 2027E EV/EBITDA.
This aggregate rating is based on analysts' research of Trevi Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TRVI Analyst Forecast & Price Prediction
Start investing in TRVI
Order type
Buy in
Order amount
Est. shares
0 shares